Sichuan Kelun Pharmaceutical Co Ltd
SZSE:002422
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
22.59
35.01
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Sichuan Kelun Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Net Income (Common)
Sichuan Kelun Pharmaceutical Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sichuan Kelun Pharmaceutical Co Ltd
SZSE:002422
|
Net Income (Common)
¥3B
|
CAGR 3-Years
36%
|
CAGR 5-Years
22%
|
CAGR 10-Years
11%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Net Income (Common)
¥3.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Net Income (Common)
¥3.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
18%
|
CAGR 10-Years
23%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Net Income (Common)
¥5.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
14%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Net Income (Common)
¥4.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
6%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Net Income (Common)
-¥780.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sichuan Kelun Pharmaceutical Co Ltd
Glance View
Nestled in the vibrant economic tapestry of China, Sichuan Kelun Pharmaceutical Co., Ltd. has emerged as a formidable player in the healthcare industry. Established in the late 1990s, the company embarked on its journey with a commitment to the development and production of intravenous infusion solutions. These infusion products have become the lifeblood of Kelun's operations, offering a critical healthcare solution that serves both domestic and international markets. By leveraging advanced technology and maintaining stringent quality control, Kelun ensures its offerings meet the diverse and demanding needs of modern medical practice. The company's narrative intertwines innovation with growth, as reflected in its expansive product range that has evolved to encompass antibiotics, traditional Chinese medicine, and comprehensive research in biotechnology. But Kelun's story doesn't stop there; it stands out in the pharmaceutical landscape through its integrated business model. By investing heavily in research and development, Kelun fuels its pipeline with new drugs, ensuring a steady stream of clinically effective and market-ready products. It also navigates strategic alliances and collaborations, stitching together a network that amplifies its market penetration and operational scalability. These moves not only consolidate its standing in the healthcare sector but also streamline supply chains, thereby optimizing revenues. With an agile approach that adapts to regulatory changes and market dynamics, Sichuan Kelun Pharmaceutical continues to script a narrative of resilience and business acumen in the global arena.
See Also
What is Sichuan Kelun Pharmaceutical Co Ltd's Net Income (Common)?
Net Income (Common)
3B
CNY
Based on the financial report for Sep 30, 2024, Sichuan Kelun Pharmaceutical Co Ltd's Net Income (Common) amounts to 3B CNY.
What is Sichuan Kelun Pharmaceutical Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
11%
Over the last year, the Net Income (Common) growth was 31%. The average annual Net Income (Common) growth rates for Sichuan Kelun Pharmaceutical Co Ltd have been 36% over the past three years , 22% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet
